|
| 34238931 | Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study. | NPJ Breast Cancer | 2021 |
| 32881987 | Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training. | PLoS One | 2020 |
| 31841354 | Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. | J Clin Oncol | 2020 |
| 30523750 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. | J Clin Oncol | 2019 |
| 31555479 | Hyperpolarised <sup>13</sup>C MRI: a new horizon for non-invasive diagnosis of aggressive breast cancer. | BJR Case Rep | 2019 |
| 29351790 | Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. | Trials | 2018 |
| 29505860 | An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. | J Clin Epidemiol | 2018 |
| 29071491 | Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. | Breast Cancer Res Treat | 2018 |
| 28716064 | Informed consent in randomised controlled trials: development and preliminary evaluation of a measure of Participatory and Informed Consent (PIC). | Trials | 2017 |
| 28222072 | Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. | Br J Cancer | 2017 |
| 29241890 | Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. | Value Health | 2017 |
| 28600210 | Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. | Lancet Oncol | 2017 |
| 28612226 | IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. | Breast Cancer Res Treat | 2017 |
| 26867046 | OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. | Health Technol Assess | 2016 |
| 27755555 | Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians' Practices across Six Randomised Controlled Trials. | PLoS Med | 2016 |
| 27130929 | Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. | J Natl Cancer Inst | 2016 |
| 27020141 | Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right. | Eur J Surg Oncol | 2016 |
| 25585651 | Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. | Histopathology | 2015 |
| 24062360 | HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice. | J Clin Pathol | 2014 |
| 24667651 | Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. | Br J Cancer | 2014 |
| 23267818 | Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. | Clin Oncol (R Coll Radiol) | 2013 |
| 24286369 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. | Breast Cancer Res | 2013 |
| 22138097 | Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. | J Natl Cancer Inst | 2012 |
| 22956732 | Functional proteomic analysis of long-term growth factor stimulation and receptor tyrosine kinase coactivation in Swiss 3T3 fibroblasts. | Mol Cell Proteomics | 2012 |
| 21741829 | Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. | Eur J Cancer | 2011 |
| 19289619 | Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. | J Clin Oncol | 2009 |
| 19802002 | The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. | Oncogene | 2009 |
| 17409432 | Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. | Cancer Res | 2007 |
| 17533402 | Predictors of ovarian reserve in young women with breast cancer. | Br J Cancer | 2007 |
| 16523200 | A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. | Br J Cancer | 2006 |
| 16006771 | Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. | Tumour Biol | 2005 |
| 14680482 | Models of breast cancer: is merging human and animal models the future? | Breast Cancer Res | 2004 |
| 15111767 | Three-dimensional in vitro tissue culture models of breast cancer-- a review. | Breast Cancer Res Treat | 2004 |
| 12912916 | Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. | EMBO J | 2003 |
| 11840567 | Cluster analysis of an extensive human breast cancer cell line protein expression map database. | Proteomics | 2002 |
| 12882523 | The application of 2D gel-based proteomics methods to the study of breast cancer. | J Mammary Gland Biol Neoplasia | 2002 |
| 12422363 | Combinatorial use of mRNA and two-dimensional electrophoresis expression data to choose relevant features for mass spectrometric identification. | Proteomics | 2002 |
| 12504007 | Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. | Mol Cell | 2002 |
| 11566615 | Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. | Endocr Relat Cancer | 2001 |
| 10768093 | Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity. | Diabetologia | 2000 |
| 10954868 | PI3-kinase inhibition: a target for drug development? | Mol Med Today | 2000 |
| 10816429 | Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. | Biochem J | 2000 |
| 10535966 | Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. | Proc Natl Acad Sci U S A | 1999 |
| 9776280 | Iodine-131-MIBG therapy of a patient with carcinoid liver metastases. | J Nucl Med | 1998 |
| 9664306 | SH2 and SH3 domains. Unraveling signaling networks with peptide antagonists. | Methods Mol Biol | 1998 |
| 9512716 | Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase. | J Mol Biol | 1998 |
| 9830063 | Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. | J Biol Chem | 1998 |
| 9337861 | Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. | Biochem J | 1997 |
| 9113989 | P110delta, a novel phosphoinositide 3-kinase in leukocytes. | Proc Natl Acad Sci U S A | 1997 |
| 8650269 | Structural and functional diversity of phosphoinositide 3-kinases. | Philos Trans R Soc Lond B Biol Sci | 1996 |